Fig. 4.
MSC/IFN-β/GFP inhibits breast tumor progression in 4 T1 tumor-bearing mice. Mice were I.V. injected MSC/IFN-β/GFP or control MSC/GFP, 1 × 106 cells/mouse through tail vein on day one after 4 T1 cell injection. 4 T1 tumors in the control group grew rapidly and all mice were euthanized on day 35 after the 4 T1 cell injection, as shown in bleft panels. Survival analysis was performed on 4 T1 tumor bearing mice treated with MSC/IFN-β/GFP compared to other two groups, P < 0.01 demonstrating a statistically significant increase in survial. Mice treated with MSC/IFN-βGFP had no 4 T1 breast tumor detectable up to 103 days after tumor cell injection, (bright panel). A representative 4 T1 breast tumor is photographed in situ (cleft panel), with metastatic tumor nodules in lungs (c, middle panel) and liver (cright panel). The survival curves of the two groups are shown in a displaying a significant difference (P < 0.001, log rank test). d shows mice injected either MSC/GFP (left panel) or not (right panel) did not affect 4 T1 tumor growth